# Supernus Pharmaceuticals, Inc. clinical trials: 64 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 64 trials with Supernus Pharmaceuticals, Inc. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Supernus Pharmaceuticals, Inc.: 64 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/supernus-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 64
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 64, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2025 | NCT07226661 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Supernus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Major Depressive Disorder (MDD) | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226661) |
| October 22, 2025 | NCT07219927 | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | Supernus Pharmaceuticals, Inc. | Observational | Recruiting | Parkinson Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219927) |
| August 26, 2025 | NCT07141329 | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | Supernus Pharmaceuticals, Inc. | Phase 2 | Enrolling by invitation | Focal Onset Seizures | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07141329) |
| January 29, 2025 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Supernus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Focal Onset Seizures | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06798896) |
| February 14, 2024 | NCT06259331 | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women | Supernus Pharmaceuticals, Inc. | Phase 4 | Completed | Healthy Lactating Women | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06259331) |
| December 29, 2023 | NCT06185985 | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms | Supernus Pharmaceuticals, Inc. | Phase 4 | Completed | Attention-Deficit/Hyperactivity Disorder | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06185985) |
| December 19, 2022 | NCT05655520 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | Supernus Pharmaceuticals, Inc. | Phase 3 | Terminated | Huntington's Disease | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05655520) |
| December 9, 2022 | NCT05645432 | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Tinnitus | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05645432) |
| November 17, 2022 | NCT05619692 | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05619692) |
| August 26, 2022 | NCT05518578 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | Supernus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Epilepsy, Seizures, Epileptic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05518578) |
| May 23, 2022 | NCT05384977 | Mass Balance Study of NV-5138 in Healthy Male Subjects | Supernus Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05384977) |
| May 3, 2022 | NCT05358821 | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Huntington Disease | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05358821) |
| April 8, 2022 | NCT05318937 | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Parkinson Disease, Cognitive Dysfunction | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05318937) |
| November 4, 2021 | NCT05107128 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Huntington's Disease | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05107128) |
| November 1, 2021 | NCT05102552 | Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects | Supernus Pharmaceuticals, Inc. | Early phase 1 | Completed | Healthy Volunteer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05102552) |
| September 28, 2021 | NCT05059600 | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting | Supernus Pharmaceuticals, Inc. | Phase 4 | Completed | Postpartum Depression | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05059600) |
| September 20, 2021 | NCT05049343 | Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy... | Supernus Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05049343) |
| March 8, 2021 | NCT04786990 | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD | Supernus Pharmaceuticals, Inc. | Phase 4 | Completed | Attention-Deficit/Hyperactivity Disorder (ADHD) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04786990) |
| March 4, 2021 | NCT04781140 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | Supernus Pharmaceuticals, Inc. | Phase 4 | Recruiting | Attention-Deficit/Hyperactivity Disorder | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04781140) |
| October 26, 2020 | NCT04602624 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to... | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Alzheimer Disease, Cognitive Dysfunction, Mild Dementia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04602624) |
| July 17, 2020 | NCT04476017 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) | Supernus Pharmaceuticals, Inc. | Phase 2 | Completed | Parkinson Disease, Cognitive Dysfunction | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04476017) |
| October 29, 2019 | NCT04143217 | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | Supernus Pharmaceuticals, Inc. | Phase 3 | Completed | Attention-Deficit/Hyperactivity Disorder | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143217) |
| August 8, 2019 | NCT04050293 | Therapy for Migraine Prevention in Children 6-11 Years of Age | Supernus Pharmaceuticals, Inc. | Phase 4 | Terminated | Migraine Disorders, Headache Disorders | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04050293) |
| July 11, 2019 | NCT04016792 | Classroom Study of SPN-812 in Children With ADHD | Supernus Pharmaceuticals, Inc. | Phase 3 | Withdrawn | ADHD | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04016792) |
| July 11, 2019 | NCT04016779 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | Supernus Pharmaceuticals, Inc. | Phase 3 | Completed | Attention-Deficit/Hyperactivity Disorder (ADHD) | 374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04016779) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 10 |
| Phase 1/2 | 4 |
| Phase 2 | 18 |
| Phase 3 | 19 |
| Phase 4 | 6 |
| Not applicable | 3 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 47 |
| Terminated | 5 |
| Recruiting | 5 |
| Approved for marketing | 2 |
| Active not recruiting | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Attention Deficit Disorder with Hyperactivity | 21 |
| Depression, Postpartum | 7 |
| Epilepsies, Partial | 5 |
| Cognitive Dysfunction | 4 |
| Parkinson Disease | 4 |
| Seizures | 4 |
| Huntington Disease | 4 |
| Epilepsy | 4 |
| Alzheimer Disease | 2 |
| Migraine Disorders | 1 |
| Headache Disorders | 1 |
| Depressive Disorder, Major | 1 |
| Tinnitus | 1 |
| Epilepsy, Complex Partial | 1 |
| Status Epilepticus | 1 |
| Conduct Disorder | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Mattress manufacturing companies in the United States](https://specstream.ai/data/businesses/mattress-manufacturing-companies/united-states)
- [Suppliers and distributors in the United States](https://specstream.ai/data/businesses/suppliers-and-distributors/united-states)
